Document Detail


Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter.
MedLine Citation:
PMID:  21084835     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The cyclin-dependent kinase inhibitor p21cip/CDKN1A is induced to promote growth arrest in response to a variety of stimuli in normal cells and loss of correct regulation of this gene is frequently observed in cancer. In particular, the upregulation of CDKN1A by p53 is considered to be a central mechanism of tumour suppression. Other transcription factors with tumour suppressor activity can also regulate CDKN1A, including the developmentally regulated factor, TFAP2A. Here we identify a novel AP-2 binding site within the proximal promoter of the CDKN1A gene and show this is required for optimal, p53-independent expression of p21cip/CDKN1A. We further describe a non-tumourgenic breast epithelial cell line model to study the role of endogenous TFAP2A and p53 in the control of drug-induced p21cip expression using ChIP. Maximal expression of CDKN1A requires TFAP2A which binds to two regions of the promoter: the proximal region where the AP-2 site lies and upstream near the major p53 binding site. The pattern of binding alters with time post-induction, with the proximal, p53-independent site becoming more important at later stages of p21cip induction. This pattern of promoter interaction by TFAP2A is distinct from that seen for the TFAP2C family member which represses CDKN1A expression.
Authors:
Angelo G Scibetta; Ping-Pui Wong; KaYi V Chan; Monica Canosa; Helen C Hurst
Related Documents :
1321335 - Gtpase-activating protein sh2-sh3 domains induce gene expression in a ras-dependent fas...
21308375 - Bone morphogenic protein--mrna upregulation after exposure to low frequency electric fi...
21467165 - Expression of id-1 is regulated by mcam/muc18: a missing link in melanoma progression.
9211355 - Modulation of c-fos and egr-1 expression in the isolated perfused kidney by agents that...
8608965 - Multifocal heterogeneity in villin and ep-cam expression in barrett's esophagus.
15926855 - Inhibition of micro-rna-induced rna silencing by 2'-o-methyl oligonucleotides in drosop...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cell cycle (Georgetown, Tex.)     Volume:  9     ISSN:  1551-4005     ISO Abbreviation:  Cell Cycle     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-12-22     Completed Date:  2011-03-23     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  101137841     Medline TA:  Cell Cycle     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4525-32     Citation Subset:  IM    
Affiliation:
Centre for Tumour iology, Institute of Cancer, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Base Sequence
Binding Sites
Cell Line, Tumor
Chromatin Immunoprecipitation
Cyclin-Dependent Kinase Inhibitor p21 / genetics,  metabolism*
Humans
Promoter Regions, Genetic*
Protein Binding
Transcription Factor AP-2 / metabolism*
Tumor Suppressor Protein p53 / genetics,  metabolism
Grant Support
ID/Acronym/Agency:
C6775/A6250//Cancer Research UK
Chemical
Reg. No./Substance:
0/Cyclin-Dependent Kinase Inhibitor p21; 0/TFAP2A protein, human; 0/Transcription Factor AP-2; 0/Tumor Suppressor Protein p53
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 conco...
Next Document:  STAT1 interacts directly with cyclin D1/cdk4 and mediates cell cycle arrest.